ASCO 2022 | ​​NRG-HN002: chemoradiotherapy for p16-positive low-risk HPV-associated oropharyngeal carcinoma

Sue S. Yom, MD, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the randomised Phase II NRG-HN002 trial (NCT02254278), which investigated chemoradiotherapy for patients with p16-positive low-risk HPV-associated oropharyngeal carcinoma. Patients were randomised to receive either 60 Gy intensity-modulated radiation therapy with concurrent cisplatin (IMRT-C) or 60 Gy accelerated IMRT. The primary endpoints were progression-free survival (PFS) of 85% at 2-years and acceptable swallowing toxicities. Both arms of the trial achieved acceptable swallowing outcomes and the chemoradiotherapy arm achieved a significantly higher PFS, which has led to this treatment regimen being taken forward into further trials (NRG-HN005, NCT03952585). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.